1. In this large and diverse genetic study, researchers identified new loci, biological pathways, and possible drug targets for future Alzheimer’s disease (AD) research and provided a more accurate estimate of AD heritability.

Evidence Rating Level: 3 (Average)

Study Rundown: Current Alzheimer’s disease (AD) treatments have limited scope and efficacy on the pathology of dementia. With the prevalence expected to double in the next 25 years, new drug targets and earlier intervention are needed. Uffelmann and colleagues performed a case-control genome-wide association study (GWAS) and meta-analyses with 109,479 cases, 74,141 proxy cases, 2,131,799 controls and 499,708 proxy controls from multi-ethnic backgrounds to investigate heritable and biological mechanisms of AD. Researchers used various methods to analyze and identify high-risk loci, possible druggable genes, immune pathways, cell type, and polygenic score (PGS) for AD. They found 41 new loci among 118 loci in total associated with AD risk; identified multiple new genes and biological pathways as candidate drug targets; showed a significant association between overexpression in microglia and underexpression in GABAergic neurons of AD-associated genes; and provided an updated single-nucleotide polymorphism (SNP)-based heritability estimate of 16%. This study’s limitations are a low relative number of non-European ancestry cases and controls, variation in the cohorts reporting of participant characteristics and AD ascertainment, as well as possible statistical bias introduced when using proxy cases and controls, although no effect has been seen on loci identification. This study identified multiple new and known pathways for further investigation in AD physiology, heritability, and treatment.

Click here to read the study in Nature

In-Depth [case-control meta-analyses]: This study examined case-controls across 30 cohorts for a GWAS analysis for AD-risk loci, potential drug targets and biological pathways, and heritability estimates. The cohorts included 109,479 AD cases, 74,141 proxy AD cases, 2,131,799 controls and 499,708 proxy controls. Total effective sample size was 416,493. Ancestry demographics were as follows: 91% European (EUR), 5% African (AFR), 3% East Asian (EAS), <1% admixed American (AMR), and <1% South Asian (SAS). An AD GWAS for the ancestry groups with effective sample sizes of 379,465 for EUR, 21,163 for AFR, 13,790 for EAS, 1,222 for AMR, and 852 for SAS. Researchers used an inverse-variance-weighted fixed-effects meta-analysis with quality control of 8,152,095 SNPs and found a significant association with AD risk in 118 loci (P < 5 × 10−8), 41 of which had not been previously identified. Seventeen of these genes were found to interact with drugs approved for conditions other than AD. Five genes of the 48 new ones were active with other genes across the amyloid processing and microglial response to amyloid-β pathways. Another five were already known to be associated with other neurodegenerative diseases. A secondary GWAS of the X chromosome was performed on a subset with a total effective sample size of 196,822. The X chromosome analysis found no risk loci. Sex-stratified secondary meta-analyses were performed on 20,402 female cases and 261,889 female controls, and 15,689 male cases and 214,956 male controls. Twelve loci and six loci were identified in the female-only and male-only GWAS, respectively. The odds ratio for the SNP associated with APOE-ε4 in female cases was 13% larger than in male cases (2.85 versus 2.52, P = 9 × 10−8).  Biological mechanisms previously identified through GWAS – lipid binding, immune activation, amyloid catabolism, and cell adhesion – and mechanisms associated with AD but through other methods than GWAS – EphrinB reverse signaling, glutathione metabolism, RAS signaling, sphingolipid metabolism, and synapse endocytosis – were connected to AD pathology through exploratory gene set enrichment analyses. After repeating the analysis on a new cohort of cases, only the immune activation and amyloid catabolism sets were still significantly associated with AD development. In an exploratory cell-type-specific gene expression analysis, researchers found a significant positive association between the GWAS signal and microglial overexpression in healthy controls. Cell-type-specific differential gene expression analysis showed significant associations in gene upregulation in microglia and downregulation in GABAergic neurons between AD cases and controls. All cell-type-specific analyses were robust to the removal of chromosome 19 and proxy phenotype data. Upregulation in microglia remained a significant association (P = 1.58 × 10−6), while downregulation in neurons became a less significant association (P < 0.05) when cell-type differential gene expression was corrected. Researchers used SBayesRC with their meta-analysis of the EUR cases in a secondary analysis to estimate a new SNP-based heritability estimate of 16% (s.e. = 0.2%) using a population prevalence of 5%. Using the same method, heritability estimates for EAS were 13% (s.e. = 4%) and for AFR were 10% (s.e. = 6%). Researchers then used their SBayesRC-based PGS on unrelated individuals in a cohort excluded from the PGS and found a respective threefold and sevenfold increased case prevalence in the top 10% compared to both the whole sample and bottom 10%. This study showed results consistent with the literature for AD-relevant genes and pathways, as well as adding new AD data on potential druggable genes, cell-type enrichment, and heritability and polygenic prediction scores. Uffelmann and colleagues have made the summary statistics from their analyses publically available to aid in further research.

Citation: Uffelmann E, Wightman DP, Bahrami S, Shadrin AA, Fominykh V, Ojima T, et al. Alzheimer’s disease genetics converges on microglial and neuronal dysregulation. Nature. 2026 Oct 28. doi: 10.1038/s41586-026-11206-y. Epub ahead of print. PMID: 42951976.